Lion TCR’s Post

Sunday 4 February is #WorldCancerDay.   It's a reminder that healthcare services around the world are working alongside patients to combat this multi-faceted disease, and that Belgium has one of the best cancer care systems in the world. 🏥   But the battle goes on 🥷, particularly in the field of research, which promises great advances in the coming years with new treatments.   WE Life Sciences actively supports companies in this sector by contributing to their funding.   In the curative field, some are just starting their research, such as EsoBiotec and THERAtRAME, while others are in clinical development, such as EPICS Therapeutics, iTeos Therapeutics, PDC*line Pharma, Celyad Oncology or Curewiki. 🧪   In diagnostics, Wallonie Entreprendre is a partner of OncoDNA, Radiomics.bio and Belgian Volition SA and, in oncology medical equipment, of IBA or Elysia-raytest   We are proud to contribute to this research in the service of humanity and the Walloon ecosystem, which is particularly successful in this field. Let's make sure we remain leaders in this marathon. 🚀   #wordcancerdy #innovation #lifesciences #pharma #investsment Caroline THIELEN Gery Lefebvre Franssen Christina Valentin TONNEL Sophie Sauvage Anne VEREECKE Fondation Cancer

#Mirxes is honoured and delighted to have Deputy Prime Minister, Coordinating Minister for Economic Policies and Chairman of the National Research Foundation, Mr Heng Swee Keat inaugurate the NUH Diagnostic Molecular Oncology Centre (DMOC) @ Biopolis, Singapore's first public-private partnership centre for specialty molecular testing, yesterday. Dr Lihan Zhou, Co-Founder and CEO of Mirxes shared, “The inauguration of the NUH DMOC@Biopolis is a significant milestone in Singapore's journey towards a future of advanced and accessible precision medicine. This public-private partnership is a landmark achievement, leveraging Mirxes' leading technology and NUH's pathology expertise. Together, we're transforming cancer care for all patients in Singapore and the region through NGS.” The Centre offers the APEX (Actionable, Personalized, EXpress) cancer treatment selection test, a cutting-edge 50-gene targeted Next Generation Sequencing (NGS) panel, which reduces costs by more than 50% for patients, has a faster turnaround time of just eight working days, and provides improved patient access. Too Heng-Phon Wee Joo Chng Soo-Yong Tan Chorh Chuan Tan Photo credit: National University Hospital #preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetection #earlydetectionsaveslives #healthcare #cancerearlydetection #NGS #Genomics #Biotech #NGSSequencing #GenomicsResearch #NextGenSequencing #DNASequencing #GenomeAnalysis

Did you know that Americas Health Foundation works tirelessly to increase access to care in LATAM? Outputs from our latest consensus conference, this time on biosimilars and interchangeability, will codify recommendations with emphasis on LMICs in a forthcoming publication. #AHF #LatinAmerica #Access #Patients

EU Clinical Trials Regulation 536/2014 and CTIS…… The Panel “EU Clinical Trials Regulation 536/2014 and CTIS – Stakeholder experiences from the Transition Period” at EUCROF24 was given by: > Eva Hrušková Reinová, SUKL > Georg Schmidt, AKEK > Pierre-Frédéric Omnes, TransPerfect Life Sciences > Stéphanie Kromar, EORTC - European Organisation for Research and Treatment of Cancer This presentation shared experiences from key stakeholders regarding Clinical Trial Regulation (CTR) 536/2014, and the IT tool Clinical Trial Information System (CTIS). #clinicalresearch #clinicaltrials #clinicaloperations #gcp #bigpharma #dct #eucrof24  

Nested Therapeutics’ lead program, NST-628, is an oral, brain-penetrant pan-RAF-MEK non-degrading molecular glue that lacks paradoxical pathway activation through the prevention of RAF paralog heterodimerization. By inhibiting the phosphorylation and activation of MEK by RAF, NST-628 targets a critical step in the RAS/RAF/MAPK signaling pathway. Preclinically, NST-628 results in broad efficacy, high tolerability, CNS activity across various RAS- and RAF-driven tumor models, and has the potential to deliver transformative clinical benefits both as a monotherapy and as a key component in combination therapies. Now, NST-628 has advanced to a Ph. I trial in patients with refractory MAPK pathway mutated/dependent advanced solid tumors. Chemenu has been working to develop more compounds for drug discovery. Here come the building blocks we can provide: https://lnkd.in/gZiEtnBV # NST-628 # Molecular Glue # RAF # MEK # RAS # MAPK # Chemenu # Building Blocks

We're excited to share some major updates from Alpha Tau Medical as we continue to advance in our mission. 🔑 Key Achievements ▪️Clinical Progress: In May, we successfully completed the first Alpha DaRT treatment for a patient with liver metastases from colorectal cancer at McGill University in Canada. ▪️Data Publication: In June, long-term safety and efficacy data on superficial cancer treatments were published in the Cancers journal, showing a nearly 100% overall response rate in treated lesions and an estimated 77% two-year recurrence-free survival rate. ▪️Technological Competitiveness: We've confirmed the applicability of Alpha DaRT across various cancer types, with particular effectiveness in hard-to-treat cancers, which is expected to draw significant market interest. ▪️Manufacturing Capacity: We received approval for a new manufacturing facility in Hudson, New Hampshire, and have initiated renovations. 🪙 Financial Status ▪️First Half Results: Net loss of $15.4 million with cash reserves of $74.1 million. We have secured enough funds for at least two years of operations, maintaining a prudent cash burn rate in line with ongoing R&D investments, ensuring sufficient capital until FDA approval. Alpha Tau remains committed to securing FDA approval by 2026, with enough operational funding secured for the next two years. They are focused on achieving our business milestones while ramping up IR and NDR activities in the U.S. to engage and inform investors. #AlphaTau #CancerTreatment

🔖 We're pleased to share that Heidelberg Pharma AG was featured in Biocentury, in an article titled - Cambrian explosion of ADCs at AACR24 - spotlighting the groundbreaking advancements in #ADCs at #AACR2024. 🔖   The article highlights our #ATAC platform, and its exceptional versatility in targeting both proliferating and quiescent tumour cells. 📚 Read the full article here: https://bit.ly/3VUAb8h   During AACR, we presented Phase I/IIa data on our lead ATAC compound, HDP-101, designed to target BCMA. Promising results were observed in multiple #myeloma patients, with notable responses and manageable side effects.   We look forward to sharing further insights at our R&D webinar on 23 April at 16.00 CEST/15.00 BST, where you can hear directly from the Heidelberg Pharma team, alongside leading Key Opinion Leaders. 🎯 Register to attend the R&D webinar here https://bit.ly/3VYr4U7 #ATAC #ADC #CancerResearch

Infuse your knowledge with the latest in TPD on 10th July at the free 5th Virtual Bio-Techne TPD and Induced Proximity Symposium ☕🔬   This event is steeped in innovation and ground-breaking research, and exciting is certainly brewing here.   We have an exclusive first public presentation of new induced proximity research from Basel Karim from the Gray Lab at Stanford, new data of a novel mechanism of action from Scott Hughes at Amphista Therapeutics Limited, impressive unbiased discovery of protein degraders and stabilizers from Juline Poirson, wonderful insights into mechanisms of degrader-targeted protein ubiquitinability from Charlotte Crowe from the Centre for Targeted Protein Degradation, utilizing degradation of HIV-1 Nef as an antiretroviral drug development approach from Tom Smithgall, and development of a versatile minimal tag to expedite degrader development projects from Breanna Zerfas at Dana-Farber Cancer Institute. 🗓 Date: July 10, 2024 🕒 Time: 7-10am PDT / 10am-1pm EDT / 3-6pm BST ✏ Register here: https://lnkd.in/exY6BzuJ Sip at your own pace – the event will be on-demand for all registrants. #proteindegradation #biotechne #TPD #inducedproximity

Introducing oNKo-044 🔦 At oNKo-innate, we’re relentlessly pursuing the goal of creating #cytokinetherapies that trigger the elimination of tumors without causing systemic toxicity. With this in mind, we created oNKo-044 using the many learnings from our oNKo-001 program, amplifying its anti-tumour activity. 🔥 oNKo-044 is a next-generation, potency-optimized IL-12 cytokine-antibody fusion molecule. Our scientists have carefully engineered this candidate to deliver an unprecedented therapeutic index for this drug class. 💉 By including a targeting arm for a surface protein expressed specifically by key tumor-infiltrating lymphocytes, the oNKo-044 molecule exhibits enhanced activity within the tumor while avoiding circulating lymphocytes that are typically associated with toxic side effects. For more information about oNKo-044 and our other pipeline assets, follow the link below 👇 https://lnkd.in/gFr8r7Pa #cytokinetherapy #immunotherapy #immunooncology #australianbiotech #cancerresearch

Excitement mounts as the 2024 ASCO Annual Meeting approaches, promising the latest in cancer treatment breakthroughs. From May 31 to June 4, industry leaders will unveil new data on various therapies. Among them, Arcus Biosciences will present updated findings from Phase II and I/II trials of innovative immuno-oncology combinations. Notably, Arcus anticipates Phase I/II studies for etrumadenant (A2a/A2b receptor antagonist) and Phase II studies for domvanalimab (anti-TIGIT mAb) to be highlighted during ASCO 2024, marking significant upcoming catalysts. New Avenues in Gastric Cancer Treatment (Edge-Gastric) & Breakthroughs in Colorectal Cancer Research (ARC-9). - Arcus Biosciences is gearing up to present the results of the ARC-9 study, which shows that etrumadenant (AB928) is safe and effective in mCRC patients. - The EDGE-Gastric Arm A1 trial's findings on domvanalimab combined with zimberelimab and FOLFOX for first-line advanced gastroesophageal cancer are anticipated to steal the spotlight To know more detailed coverage, visit: https://lnkd.in/guizf6cS #ASCO2024 #CancerResearch #Immunotherapy #ArcusBiosciences #ClinicalTrials #Oncology #MedicalResearch #CancerTreatment #ImmunoOncology #Etrumadenant #Domvanalimab #PhaseII #PhaseI #TIGIT #A2a #A2b #CancerTherapies